Recursion Pharmaceuticals, Inc. (RXRX)Healthcare | Biotechnology | Salt Lake City, United States | NasdaqGS
3.34 USD
-0.10
(-2.907%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.35 +0.01 (0.299%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:23 a.m. EDT
The investment case for Recursion Pharmaceuticals is currently broken by a catastrophic failure in execution and growth. The company has delivered four consecutive years of negative annual returns, erasing over 77% of its value since the start of the observation window. This is not a temporary setback; the market has priced in a structural deterioration where revenue is shrinking and the business is burning cash without generating returns. Despite the CEO's claims of reaching an 'inflection point,' the hard data shows a company trapped in a death spiral with no visible path to profitability. The balance sheet is fragile relative to the burn rate, and the stock trades at a premium to sales despite having no earnings. While the options market shows speculative hope in deep out-of-the-money calls, the overwhelming weight of open interest in puts suggests smart money is hedging against further collapse. For a long-term investor, the fundamentals are unambiguously poor, warranting a complete avoidance of the stock until a sustained turnaround in revenue growth and margin expansion is proven. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.093688 |
| MSTL | 0.100127 |
| AutoTheta | 0.103413 |
| AutoETS | 0.105430 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 1.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.137 |
| Excess Kurtosis | -0.80 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.283 |
| Revenue per Share | 0.108 |
| Market Cap | 1,791,145,344 |
| Forward P/E | -3.73 |
| Beta | 1.05 |
| Website | https://www.recursion.com |
As of Aug. 22, 2026, 4:23 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $2.50-$3.00) across nearly all expirations, particularly the September 18th and November 20th dates where put volume dwarfs call volume. Conversely, call activity is concentrated in deep out-of-the-money strikes ($5.00-$7.00) with significant new flow, suggesting a speculative 'lottery ticket' strategy rather than a conviction bet on immediate recovery. Implied volatility remains elevated, reflecting uncertainty about whether the company can reverse its multi-year decline.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.28326178 |
| Address1 | 41 South Rio Grande Street |
| All Time High | 42.81 |
| All Time Low | 2.77 |
| Ask | 3.34 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 2.4 - Buy |
| Average Daily Volume10 Day | 17,386,720 |
| Average Daily Volume3 Month | 20,120,641 |
| Average Volume | 20,120,641 |
| Average Volume10Days | 17,386,720 |
| Beta | 1.054 |
| Bid | 2.81 |
| Bid Size | 5 |
| Board Risk | 9 |
| Book Value | 1.71 |
| City | Salt Lake City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.34 |
| Current Ratio | 5.034 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.45 |
| Day Low | 3.31 |
| Debt To Equity | 7.283 |
| Display Name | Recursion Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,931,200 |
| Earnings Call Timestamp Start | 1,785,931,200 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -471,604,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.776 |
| Enterprise To Revenue | 23.862 |
| Enterprise Value | 1,308,997,888 |
| Eps Current Year | -0.92272 |
| Eps Forward | -0.89474 |
| Eps Trailing Twelve Months | -0.97 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.3063 |
| Fifty Day Average Change | 0.03369999 |
| Fifty Day Average Change Percent | 0.01019266 |
| Fifty Two Week Change Percent | -28.326178 |
| Fifty Two Week High | 7.18 |
| Fifty Two Week High Change | -3.84 |
| Fifty Two Week High Change Percent | -0.53481895 |
| Fifty Two Week Low | 2.77 |
| Fifty Two Week Low Change | 0.56999993 |
| Fifty Two Week Low Change Percent | 0.20577615 |
| Fifty Two Week Range | 2.77 - 7.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,618,579,800,000 |
| Float Shares | 518,420,004 |
| Forward Eps | -0.89474 |
| Forward P E | -3.732928 |
| Free Cashflow | -219,493,744 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 600 |
| Fullday Change | -0.1 |
| Fullday Change Percent | -2.90698 |
| Fullday Price | 3.35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -392,600,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0228 |
| Held Percent Institutions | 0.70623 |
| Implied Shares Outstanding | 536,271,087 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-04-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. |
| Long Name | Recursion Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,791,145,344 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_261401243 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -518,884,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,862,754,566 |
| Number Of Analyst Opinions | 6 |
| Open | 3.4 |
| Operating Cashflow | -350,480,992 |
| Operating Margins | -17.59687 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 385 269 0203 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.29940093 |
| Post Market Price | 3.35 |
| Post Market Time | 1,787,961,583 |
| Previous Close | 3.44 |
| Price Eps Current Year | -3.6197329 |
| Price Hint | 4 |
| Price To Book | 1.9532163 |
| Price To Sales Trailing12 Months | 32.651768 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.672 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.42857 |
| Region | US |
| Regular Market Change | -0.1 |
| Regular Market Change Percent | -2.90698 |
| Regular Market Day High | 3.45 |
| Regular Market Day Low | 3.31 |
| Regular Market Day Range | 3.31 - 3.45 |
| Regular Market Open | 3.4 |
| Regular Market Previous Close | 3.44 |
| Regular Market Price | 3.34 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 10,526,307 |
| Return On Assets | -0.27334 |
| Return On Equity | -0.5658 |
| Revenue Growth | -0.601 |
| Revenue Per Share | 0.108 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 535,342,170 |
| Shares Percent Shares Out | 0.3318 |
| Shares Short | 177,923,359 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 180,760,541 |
| Short Name | Recursion Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.3479 |
| Short Ratio | 10.29 |
| Source Interval | 15 |
| State | UT |
| Symbol | RXRX |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.21667 |
| Target Median Price | 7.0 |
| Total Cash | 545,683,008 |
| Total Cash Per Share | 1.019 |
| Total Debt | 66,638,000 |
| Total Revenue | 54,856,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.97 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.6704 |
| Two Hundred Day Average Change | -0.3304 |
| Two Hundred Day Average Change Percent | -0.09001744 |
| Type Disp | Equity |
| Volume | 10,526,307 |
| Website | https://www.recursion.com |
| Zip | 84,101 |